Great Leap: Major Chinese Pharmas See Innovative Drug Sales Breakthrough in H1
Others Struggle To Raise Ratio
Executive Summary
A number of major Chinese pharma firms, including Simcere and Hansoh, brought in more revenues from innovative drugs than generics in the first half, a major stand-out from their domestic peers.
You may also be interested in...
3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Explained: How China’s Public Payer Wants To Define Innovative Drugs
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter revealed during a recent industry event. The disclosure has unnerved pharma companies, which have been hit by sharp drug price discounts that were required by the public payer in exchange for reimbursement coverage.